A Pilot (Phase 1) Study to Evaluate the Safety and Efficacy of Combination Checkpoint Blockade (Ipilimumab and Nivolumab) Plus External Beam Radiotherapy in Subjects With Stage IV Melanoma

Trial Profile

A Pilot (Phase 1) Study to Evaluate the Safety and Efficacy of Combination Checkpoint Blockade (Ipilimumab and Nivolumab) Plus External Beam Radiotherapy in Subjects With Stage IV Melanoma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Sep 2017

At a glance

  • Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions; First in man
  • Most Recent Events

    • 06 Sep 2017 According to trial design presented at the 3rd CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference, ten patients have been enrolled as of 7 Jun 2017.
    • 06 Sep 2017 Trial design presented at the 3rd CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference
    • 13 Jun 2017 According to trial design presented at the 53rd Annual Meeting of the American Society of Clinical Oncology, four patient have been enrolled as of 31 Dec 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top